Good News and Bad News for Gilead Sciences: Which Carries More Weight?
You knew it wouldn't take too long for euphoria over Gilead Sciences' (NASDAQ: GILD) planned acquisition of Kite Pharma to wear off. The question was whether the next round of news for the big biotech would be good or bad. As it turned out, Gilead has had both over the last few days.
But all news isn't equally important. Here are the good and bad recent developments for Gilead, and what the real impact of each could be.
Image source: Getty Images.
Source: Fool.com
Merck & Co. Inc. Aktie
105,00 €
0,77 %
Die Community bevorzugt klar Merck & Co. Inc. mit vielen Buy- und nur wenigen Sell-Einschätzungen.
Das Kursziel von 125 € für Merck & Co. Inc. weist auf eine leichte Verbesserung gegenüber dem aktuellen Kurs von 105.0 € hin.
